Oncología (médica)

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. Defining The Immunologic Profile Of Sentinel Lymph Nodes And Identifying The Mechanisms Responsible For Immunosuppression

   Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to look at the effects cancer and melanoma have on the immune cells found in lymph nodes.

2. Circulating Tumor DNA (cTDNA) Based in NGS (Next Generation Sequencing) Assays for Oncology Patients With Solid Tumors

   Rochester, Minn.

   The purpose of this study is to design, develop and assess the performance characteristics of NGS assays using circulating tumor DNA for the detection of mutations associated solid tumors.

   The performance characteristics of these assays for detecting ctDNA mutation in oncology patients will be assessed by comparing the mutation results obtained from these assays to those obtained by orthogonal methods, including tissue-based assays and results from a ctDNA assay by Guardant on blood.

3. Global Cardio Oncology Registry

   Rochester, Minn.

   The purpose of this study is to provide a large database and platform for prospective sub-studies and eventually develop additional collaborations with a platform for clinical studies and trials following the initial pilot phase.

4. A Prospective Ocular Tumor Study

   Rochester, Minn.

   The purpose of this study is to use clinical, imaging, molecular, and epidemiological investigation toward the goal of providing new knowledge about ocular tumors that will be useful in understanding, diagnosing, monitoring, and suggesting new avenues of treatment. This study does not involve experimental treatment of any ocular tumor, but rather observation of tumor natural history or outcomes following standard of care therapy, associated systemic and ocular conditions, and basic research investigations to better understand tumor biomarkers and pathophysiology.

5. A Study Of CGM In GBM

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this study is to compare standard glucose monitoring versus continuous glucose monitoring (CGM) with endocrinology-guided intervention in newly diagnosed glioblastoma (GBM) patients receiving standard-of-care therapy.

6. EF-41/KEYNOTE D58: Phase 3 Study Of Optune Concomitant With Temozolomide Plus Pembrolizumab In Newly Diagnosed Glioblastoma

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).

7. Wearable Artificial InTelligence For Cardiac Function And Health Monitoring

   Rochester, Minn.

   The purpose of thist study is to find a cost effective CV surveillance of cancer survivors over long periods of time to prevent the risk of progression of HF and related morbidity and mortality. Mobile device-based AI-ECG can reliably detect cardiac dysfunction in lymphoma and sarcoma survivors  and smart watch based surveillance for cardiotoxicity is feasible and reliable.

8. A Study To Evaluate EAA181 To Treat Newly-diagnosed Multiple Myeloma

   Rochester, Minn., La Crosse, Wis.

   The primary purpose of this study is to determine if bortezomib, daratumumab, lenalidomide and dexamethasone (Btz-DRd) consolidation followed by daratumumab and lenalidomide (DR) maintenance after standard induction therapy with daratumumab, lenalidomide and dexamethasone (DRd) results in superior overall survival compared to DRd consolidation followed by DR maintenance, in MRD positive patients.

9. ROF2181

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   Currently, only a few international institutions use CIRT to treat pelvic bone sarcomas. Accordingly, data evaluating the potential differences in oncological outcomes, toxicities, and functional outcomes between CIRT and the more readily accessible local therapies of surgery and PT is scarce. For this reason, we propose conducting a prospective comparative effectiveness study evaluating functional outcomes, toxicities, and local control in patients with pelvic bone sarcomas treated with surgery, PT, and CIRT.

10. Reduced Dose Hypofractionated Radiotherapy For Indolent Non-hodgkin Lymphoma

    Mankato, Minn., Rochester, Minn., Eau Claire, Wis., Jacksonville, Fla., La Crosse, Wis., Albert Lea, Minn., Scottsdale/Phoenix, Ariz.

    The purpose of thisstudy is to evaluate reduction of radiotherapy dose for patients with indolent NHL by conducting a prospective randomized phase 2 study comparing reduced dose hypofractionated ISRT of 9 Gy delivered over 3 fractions (BED 12 Gy) to standard of care 24 Gy delivered over 12 fractions (BED 29Gy), while simultaneously evaluating prognostic value of pre-radiation functional imaging parameters and molecular markers to predict treatment response and failure.